Innate Pharma First Quarter 2019 Report
Cash, cash equivalents and financial assets of the Company amounted to €237.1 million* Initiation of cohort expansion study of monalizumab and cetuximab to evaluate triple combination with an anti-PD...
Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)
Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 22, 2019, at 11:00 AM in its headquarters, 117 avenue de Luminy...
Innate Pharma highlights next generation of cancer immunotherapies at the American Association of Cancer Research (AACR) 2019 annual meeting
New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway First data presented from Innate Pharma’s...
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
Cash, cash equivalents and financial assets* amounted to €202.7m (million euros) as of December 31, 2018 (€176.6m in 2017) Revenue and other income amounted to €94.0m (€36.2m in 2017) Operating...
Innate Pharma announces the appointment of Jennifer Butler as Executive Vice President, General Manager, US
Commercial industry leader with immuno-oncology product launch experience joins Innate’s Executive Committee General Manager will lead the Lumoxiti ® transition to Innate Pharma from AstraZeneca...
Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
Appointments of Dr. Mondher Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP Business Development and Portfolio Strategy, renewed to the Executive Board for three years Innate Pharma SA...
Innate Pharma receives FDA fast track designation for IPH4102 in relapsed or refractory Sézary syndrome
Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the treatment of adult patients with relapsed or refractory Sézary syndrome (SS) who have...
Innate Pharma announces its financial calendar for 2019
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2019, which is set as follows: March 20, 2019: Publication of 2018 financial statements...
Upcoming investor conferences
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events in the first quarter 2019: - LifeSci Advisors 1x1...
Innate Pharma announces updated results that support advancement of IPH4102 in refractory Sézary syndrome at the American Society of Hematology (ASH) 2018 annual meeting
Differentiating profile of IPH4102 confirmed: high and durable response, favorable safety profile with long-term follow-up and substantial improvement in quality of life Innate Pharma expects to...